Investigations
Elanco Animal Health Incorporated
Overview
Overview
- Deadline:
- Upcoming
| Company Name: | Company Name: Elanco Animal Health Incorporated |
| Stock Symbol: | Stock Symbol: ELAN |
Elanco Animal Health Incorporated (NYSE: ELAN): Elanco is being investigated for violations of the federal securities laws in connection with potential false and misleading statements made to investors and a subsequent significant price decline in the stock.
If you incurred losses in Elanco, you are encouraged to submit your information.
Why is Elanco being Investigated?
Elanco develops products to treat diseases in animals. Two of the most important treatments in the company’s development pipeline are currently being reviewed by the U.S. Food and Drug Administration (“FDA”). The treatments are named Zenrelia, a drug for a type of dermatitis in dogs, and Credelio Quattro, which is a broad spectrum oral parasiticide covering fleas, ticks and internal parasites.
With respect to these treatments, the company stated that the FDA “has all data necessary to complete its review. All technical sections, including the label, are expected to be approved before the end of June” 2024.
However, on June 27, 2024, Elanco announced that it expected the FDA would not approve either drug in June 2024 and that Zenrelia would come with a boxed warning on safety.
The Stock Declines as the Truth is Revealed
The news of the delayed approval and boxed safety warning caused a significant 21% decline in the price of Elanco stock, from $17.97 per share on June 26, 2024 to $14.27 per share on June 27, 2024.
I Suffered Losses, What Should I Do?
If you suffered losses from your investment in Elanco, you should submit your information to speak with an attorney about your rights.
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The Firm will seek court approval for any potential fees and expenses.
You can also contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
If you incurred losses in Elanco, you are encouraged to submit your information.
Why is Elanco being Investigated?
Elanco develops products to treat diseases in animals. Two of the most important treatments in the company’s development pipeline are currently being reviewed by the U.S. Food and Drug Administration (“FDA”). The treatments are named Zenrelia, a drug for a type of dermatitis in dogs, and Credelio Quattro, which is a broad spectrum oral parasiticide covering fleas, ticks and internal parasites.
With respect to these treatments, the company stated that the FDA “has all data necessary to complete its review. All technical sections, including the label, are expected to be approved before the end of June” 2024.
However, on June 27, 2024, Elanco announced that it expected the FDA would not approve either drug in June 2024 and that Zenrelia would come with a boxed warning on safety.
The Stock Declines as the Truth is Revealed
The news of the delayed approval and boxed safety warning caused a significant 21% decline in the price of Elanco stock, from $17.97 per share on June 26, 2024 to $14.27 per share on June 27, 2024.
I Suffered Losses, What Should I Do?
If you suffered losses from your investment in Elanco, you should submit your information to speak with an attorney about your rights.
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The Firm will seek court approval for any potential fees and expenses.
You can also contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.